Invo Bioscience

INVO Bioscience has developed INVOcell, a reproductive technology that enables fertilization and early embryo development to take place within the woman’s body. INVOcell received patents and FDA clearance in 2016 and received CE mark in 2019. It is claimed to be the first Intravaginal Culture (IVC) system globally that is used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. In addition, this technology is claimed to be the only alternative to traditional in vitro fertilization with similar results.

The INVOcell holds the egg and sperm to enable fertilization and early embryo development to take place. The clinician would customize a stimulation protocol based on the patient. Some clinicians may opt for a mild stimulation which means giving fewer injections. The INVOcell is 3.8 cm in length and ~2.5 cm in width. It is reported that most patients experience little to no discomfort.

The company claims to be committed to making the fertility solutions based on INVOcell an affordable treatment option to a wider community.

In October 2023, INVO Bioscience entered into a definitive merger agreement with biotechnology company NAYA Biosciences in an all-stock transaction. The deal values INVO at USD 12.4 million and NAYA at USD 90.8 million. Following the merger, the combined company was expected to operate under the name "NAYA Biosciences." However, in November 2023, the company received notice from The Nasdaq informing that it has regained compliance with the minimum stockholders' equity requirement under NASDAQ Listing Rules. The Company was subject to a mandatory panel monitor for a period of one year from the date of the notification.

Key customers and partnerships

INVO Bioscience entered into an exclusive distribution agreement with Taiwan-based Ming Mei Technology in January 2023 for an initial 1-year term with renewals. Ming Mei is a largee distributor of fertility-based devices and components in Taiwan focusing on bringing the latest and most advanced medical equipment into the region.

Funding and financials

The company raised USD 4.5 million in August 2023 in a post-IPO equity round.